
Metagenomi Inc (MGX) Stock Forecast & Price Target
Metagenomi Inc (MGX) Analyst Ratings
Bulls say
Metagenomi Therapeutics Inc. has developed a comprehensive genome editing toolbox that supports both small and large-scale genomic alterations, positioning the company favorably within the genetic medicines sector. The company’s focus on in vivo gene editing, demonstrated through promising results such as sustained FVIII levels of 80% over 19 months in preclinical models, showcases its potential to address significant health conditions including Hemophilia A and cardiovascular diseases. This robust pipeline, combined with the strategic pursuit of technology licensing for ex vivo cell therapy, underscores a strong growth trajectory and long-term value proposition for investors.
Bears say
Metagenomi Therapeutics Inc reported a substantial net loss of $19.9 million for the second quarter of 2025, translating to a loss of $0.54 per share, which raises concerns regarding its financial sustainability. The company faces significant risks associated with potential delays in advancing its pipeline candidates through clinical assessments and the possibility of generating unfavorable clinical data, particularly for key programs such as Hemophilia A. Additionally, there are long-term dilution risks that may negatively impact shareholder value, contributing to a broader negative outlook for the stock.
This aggregate rating is based on analysts' research of Metagenomi Inc and is not a guaranteed prediction by Public.com or investment advice.
Metagenomi Inc (MGX) Analyst Forecast & Price Prediction
Start investing in Metagenomi Inc (MGX)
Order type
Buy in
Order amount
Est. shares
0 shares